News Search Results
Sep 06, 2025, 09:33 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Sep 05, 2025, 07:05 ET REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II
to the central nervous system (CNS). Delivery of the IDS gene within cells in the CNS could provide a permanent source of secreted iduronate-2-sulfatase (I2S) protein beyond the blood-brain barrier, allowing for long-term cross correction of cells throughout the CNS. RGX-121 expressed protein is
More news about: REGENXBIO Inc.
Sep 04, 2025, 22:00 ET Medidata Secures a Leader Position in Everest Group's PEAK Matrix® Assessment for eCOA, Driving the New Patient Experience Forward
Cogstate, Medidata eCOA was further enhanced with scientific rigor that aims to reduce rater burden and enhance signal detection in Central Nervous System (CNS) trials. "Achieving a Leader position in Everest Group's eCOA PEAK Matrix® Assessment underscores Medidata's relentless pursuit of innovation
More news about: Medidata
Sep 04, 2025, 11:35 ET RNAi Technology Market Size to Reach USD 6.63 Billion with 10.4% CAGR by 2033, Report by DataM Intelligence
supportive pathways such as orphan drug and breakthrough designations. RNAi is no longer confined to rare disease therapies but is poised to tackle oncology, CNS disorders, and infectious diseases. By silencing disease-causing genes with precision, RNAi is amplifying not only clinical outcomes but also its market
More news about: DataM Intelligence 4 Market Research LLP
Sep 04, 2025, 08:16 ET Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
platform by innovators like Hoth Therapeutics. This online service, which is a part of our RADR platform, has the potential to be a game-changer in CNS drug development. This cutting-edge AI tool, with its 94% accuracy in predicting blood-brain barrier permeability, is empowering researchers to make
More news about: Hoth Therapeutics, Inc.
Sep 04, 2025, 07:00 ET AL-S Pharma announces positive topline results from Phase 2 study of AP-101 for the treatment of amyotrophic lateral sclerosis (ALS)
NeurimmuneNeurimmune is a biopharmaceutical company translating human immune memory into antibody therapeutics. Neurimmune develops drug candidates for CNS and related protein aggregation diseases including Alzheimer's disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. With its Reverse Translational
More news about: AL-S Pharma AG
Sep 04, 2025, 06:45 ET Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers
approved tests. Olomorasib is a potent and highly selective second-generation inhibitor of KRAS G12C with preliminary evidence of central nervous system (CNS) activity. Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition
More news about: Eli Lilly and Company
Sep 03, 2025, 10:10 ET Heterocyclic and Fluoro Organic Compounds Market to Reach $1,213.5 Million by 2035, Growing at 7.2% CAGR - Vantage Market Research
Heterocyclic and Fluoro Organic Compounds Market? Pharmaceutical Innovation: Rising demand for heterocyclic scaffolds in oncology, CNS, and antiviral therapies.Agrochemicals: Fluorinated molecules enhance crop protection efficacy and stability, supporting sustainable agriculture.Advanced
More news about: Vantage Market Research
Sep 03, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Sep 03, 2025, 09:02 ET Julius Clinical Expands CNS and Cardiometabolic Capabilities with Post-Merger Growth and New Operations in Spain and Germany
2025 /PRNewswire/ -- Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic indications, today announced continued growth in bookings in these key therapeutic areas during the second quarter of 2025. This
More news about: Julius Clinical
Sep 02, 2025, 17:02 ET 3-minute EEG Test Reliably Detects Memory Impairment, Enabling Earlier Alzheimer's Diagnosis
NeuroscienceWith a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq®, an AI-based, multi-domain digital biomarker
More news about: Cumulus Neuroscience
Sep 02, 2025, 08:00 ET CRC Appoints Jason Casarella, MBA as Chief Commercial Officer
chapter of growth as the partner of choice in CNS clinical research. About Cognitive Research CorporationCognitive Research Corporation (CRC) is a leading full-service clinical research organization, specializing exclusively in CNS disorders, including neurology, psychiatry, and
More news about: Cognitive Research Corporation
Aug 29, 2025, 10:44 ET Expert Panel to Discuss Innovations in Alzheimer's Disease Clinical Trials
academia on the transformative power of at-home and in-clinic innovations in central nervous system (CNS) clinical trials. Attendees will learn how digital biomarkers have the potential to transform CNS clinical trials much the same way that next-generation sequencing has transformed oncology, enabling
More news about: Xtalks
Aug 29, 2025, 08:00 ET Nota AI Showcases Generative AI-Based Next-Gen Traffic Innovation at ITSWC 2025, Demonstrating Leadership on the Global Stage
Successful U.S. PoC with Sony underscores accelerated global market expansionJoint showcases with Korea Pavilion, hosted by MOLIT•LG CNS highlight Korea's leadership and the global competitiveness of ITS technologySEOUL,
More news about: Nota AI
Aug 29, 2025, 01:23 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
maximum daily dose of 12 mL; essentially 'sodium-free'. Contains glucose - may be harmful to teeth. Interactions: Pharmacodynamic interactions with other CNS depressants increase the risk of aggravated central nervous system depression. An increase in dose may be necessary when coadministered with rifampicin
More news about: UCB
Aug 29, 2025, 01:15 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
maximum daily dose of 12 mL; essentially 'sodium-free'. Contains glucose - may be harmful to teeth. Interactions: Pharmacodynamic interactions with other CNS depressants increase the risk of aggravated central nervous system depression. An increase in dose may be necessary when coadministered with rifampicin
More news about: UCB
Aug 28, 2025, 18:27 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 18:22 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 18:22 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 18:19 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 18:17 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Aug 28, 2025, 17:31 ET GSK 3 Inhibitor Market Landscape Shows Promising Upswing as Growing Interest in Targeted Therapies | DelveInsight
nuclear GSK-3β. AMO Pharma is developing AMO-02 (tideglusib) for congenital myotonic dystrophy, with potential applications in other CNS, neuromuscular, and orphan diseases. This clinical-stage investigational drug targets the severe form of congenital myotonic dystrophy (DM1 or Steinert
More news about: DelveInsight Business Research, LLP
Aug 28, 2025, 09:00 ET D3 Bio, Inc. Announces FDA Breakthrough Therapy Designation and Orphan Drug Designation for D3S-001 for the Treatment of Patients with KRAS G12C-Mutated Cancers
protein. In preclinical investigations, D3S-001 demonstrated high covalent potency, complete engagement of KRAS G12C at clinically relevant doses and CNS penetration properties. D3S-001 is currently under evaluation as monotherapy and in combination regimens in a Phase II global clinical trial in patients
More news about: D3 Bio, Inc.
Aug 28, 2025, 08:30 ET Innovations in Alzheimer's Disease Clinical Trials: Digital Endpoints - Upcoming Expert Panel Discussion Hosted by Xtalks
academia on the transformative power of at-home and in-clinic innovations in central nervous system (CNS) clinical trials. Attendees will learn how digital biomarkers have the potential to transform CNS clinical trials much the same way that next-generation sequencing has transformed oncology, enabling
More news about: Xtalks
Aug 28, 2025, 07:00 ET Major European Financial Institution Selects Corero Network Security in Multi-Year Deal to Safeguard Critical Infrastructure
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced it has secured a multi-year
More news about: Corero Network Security